1. Ahrendt H, et al. Efficacy, Acceptability and Tolerability of the Combined Contraceptive Ring NuvaRing, Compared With an Oral Contraceptive Containing 30 μg of Ethinyl Estradiol and 3 mg of Drospirenone. Contraception 74(6): 451-457, Sep 2006.
2. Datos en archivo , MSD.
3. van den Heuvel M, et al. Comparison of Ethinylestradiol Pharmacokinetics in Three Hormonal Contraceptive Formulations: The Vaginal Ring, the Transdermal Patch and an Oral Contraceptive. Contraception 72(3): 168-174, Sep 2005.
4. Timmer C, et al. Pharmacokinetics of Etonogestrel and Ethinylestradiol Released From a Combined Contraceptive Vaginal Ring. Clinical Pharmacokinetics 39(3): 233-242, Sep 2000.
5. Alexander NJ, et al. Why consider vaginal drug administration?. Fertil Steril. 2004 Jul;82(1):1-12.
6. Barnhart K, et al. In Vivo Assessment of NuvaRing Placement. Contraception 72(3): 196-199, Sep 2005.
7. Dieben T, et al. Efficacy, Cycle Control, and User Acceptability of a Novel Combined Contraceptive Vaginal Ring. Obstetrics and Gynecology 100(3): 585-593, Sep 2002.
8. Oddson K, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005 Feb;20(2):557-62.
9. Ahrendt HJ. et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006 Dec;74(6):451-7
10. Oddsson K. et al. Efficacy and safety of a contraceptive vaginal ring compared whit a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005 Mar;71(3):176-82.
11. Novák A, et al. The Combined Contraceptive Vaginal Ring, NuvaRing: An International Study of User Acceptability. Contraception 67(3): 187-194, Mar 2003.